Value-Based Cancer Care Web Exclusives

June 2017

Additional Interventions Do Not Boost Outcomes Over Single Transplant in Patients with Multiple Myeloma

Phoebe Starr

Multiple Myeloma

Additional interventions after upfront autologous hematopoietic stem-cell transplantation (HSCT) in patients with multiple myeloma failed to provide further improvement in progression-free survival (PFS) or overall survival (OS) compared with single autologous HSCT, according to results from the multicenter STaMINA clinical trial presented at the 2016 American Society of Hematology meeting. [ Read More ]